JNK regulation of hepatic manifestations of the metabolic syndrome

Trends in Endocrinology and Metabolism

Volumn 21, Issue 12, 2010, Pages 707-713

  Czaja, Mark J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

CLINICAL FEATURE; DISEASE COURSE; FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; FATTY LIVER; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; METABOLIC SYNDROME X; MODELS, BIOLOGICAL;

EID: 78650280416     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.08.010     Document Type: Review

References (65)

1. Eckel R.H., et al. The metabolic syndrome. Lancet 2005, 365:1415-1428.
2. Blazer D.G., et al. Metabolic syndrome predicts mobility decline in a community-based sample of older adults. J. Am. Geriatr. Soc. 2006, 54:502-506.
3. Hassinen M., et al. Metabolic syndrome and the progression of carotid intima-media thickness in elderly women. Arch. Intern. Med. 2006, 166:444-449.
4. Powell E.E., et al. Dangerous liaisons: the metabolic syndrome and nonalcoholic fatty liver disease. Ann. Intern. Med. 2005, 143:753-754.
5. de Marco R., et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999, 22:756-761.
6. Gastaldelli A., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49:1537-1544.
7. Soderberg C., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
8. Adams L.A., Lindor K.D. Nonalcoholic fatty liver disease. Ann. Epidemiol. 2007, 17:863-869.
9. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 2002, 12:14-21.
10. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
11. Bogoyevitch M.A., Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol. Mol. Biol. Rev. 2006, 70:1061-1095.
12. Sabapathy K., et al. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 2004, 15:713-725.
13. Jaeschke A., et al. JNK2 is a positive regulator of the cJun transcription factor. Mol. Cell 2006, 23:899-911.
14. 307. J. Biol. Chem. 2000, 275:9047-9054.
15. Hirosumi J., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
16. Tuncman G., et al. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10741-10746.
17. Schattenberg J.M., et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43:163-172.
18. Larter C.Z., Yeh M.M. Animal models of NASH: getting both pathology and metabolic context right. J. Gastroenterol. Hepatol. 2008, 23:1635-1648.
19. Schattenberg J.M., Galle P.R. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig. Dis. 2010, 28:247-254.
20. Rinella M.E., Green R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol. 2004, 40:47-51.
21. Singh R., et al. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2008, 49:87-96.
22. Kisseleva T., Brenner D.A. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J. Gastroenterol. Hepatol. 2007, 22:S73-S78.
23. Kluwe J., et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010, 138:347-359.
24. Kodama Y., et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 2009, 137:1467-1477.
25. Malhi H., et al. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 2006, 281:12093-12101.
26. Solinas G., et al. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16454-16459.
27. Lim J.S., et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:251-264.
28. Wei Y., et al. Fructose selectively modulates c-jun N-terminal kinase activity and insulin signaling in rat primary hepatocytes. J. Nutr. 2005, 135:1642-1646.
29. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
30. Li Z., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
31. Liu H., et al. NF-κB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 2002, 35:772-778.
32. Wang Y., et al. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J. Biol. Chem. 2006, 281:15258-15267.
33. Cani P.D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
34. Mencin A., et al. Toll-like receptors as targets in chronic liver diseases. Gut 2009, 58:704-720.
35. Rivera C.A., et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007, 47:571-579.
36. Saberi M., et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab. 2009, 10:419-429.
37. Spruss A., et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50:1094-1104.
38. Leclercq I.A., et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 2000, 105:1067-1075.
39. Sanyal A.J., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
40. Lieber C.S. CYP2E1: from ASH to NASH. Hepatol. Res. 2004, 28:1-11.
41. Liu H., et al. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-α. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G257-G266.
42. Schattenberg J.M., et al. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J. Biol. Chem. 2005, 280:9887-9894.
43. Kapoor A., Sanyal A.J. Endoplasmic reticulum stress and the unfolded protein response. Clin. Liver Dis. 2009, 13:581-590.
44. Ozcan U., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
45. Urano F., et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000, 287:664-666.
46. Delibegovic M., et al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes 2009, 58:590-599.
47. Ozcan U., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
48. Donnelly K.L., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
49. Nakatani Y., et al. Modulation of the JNK pathway in liver affects insulin resistance status. J. Biol. Chem. 2004, 279:45803-45809.
50. Yu X.X., et al. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E436-E445.
51. Yang R., et al. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor γ coactivator 1β and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J. Biol. Chem. 2007, 282:22765-22774.
52. Vijayvargia R., et al. JNK deficiency enhances fatty acid utilization and diverts glucose from oxidation to glycogen storage in cultured myotubes. Obesity (Silver Spring) 2010, 18:1701-1709.
53. Rozo A.V., et al. Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes. Diabetologia 2008, 51:1493-1504.
54. Sabio G., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
55. Schattenberg J.M., Czaja M.J. TNF and TNF receptors. Signaling Pathways in Liver Diseases 2010, 161-179. Springer-Verlag. 2nd edn. J.F. Dufour, P.-A. Clavien (Eds.).
56. Cazanave S.C., et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J. Biol. Chem. 2009, 284:26591-26602.
57. Sabio G. Prevention of steatosis by hepatic JNK1. Cell Metab. 2009, 10:491-498.
58. Singh R., et al. Autophagy regulates lipid metabolism. Nature 2009, 458:1131-1135.
59. Wei Y., et al. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol. Cell 2008, 30:678-688.
60. Solinas G., et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007, 6:386-397.
61. Vallerie S.N., et al. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008, 3:e3151.
62. Ablamunits V., et al. Reduced adiposity in ob/ob mice following total body irradiation and bone marrow transplantation. Obesity (Silver Spring) 2007, 15:1419-1429.
63. Emanuelli B., et al. Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3545-3550.
64. Kaneto H., et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat. Med. 2004, 10:1128-1132.
65. 2-terminal kinase and serine phosphorylation of IRS-1 in the liver of ZDF rats. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E671-E682.